Century of Progress on the Structure of APOB-100 in Atherogenic Lipoproteins.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing structural biology and biochemical mechanisms without new human clinical or trial data.
PubMed 42241510 · doi:10.1161/CIRCRESAHA.126.328575
What was done
This narrative review synthesized the historical progression and recent advancements in determining the structure of apolipoprotein B-100 (APOB-100) on atherogenic lipoproteins (VLDL, IDL, and LDL). It evaluated insights derived from classical biochemical techniques (mutagenesis, antibody mapping, chemical cross-linking) alongside modern near-atomic cryo-electron microscopy (cryo-EM) architectures and integrative modeling.
What was found
The abstract reports no quantitative values or statistical metrics. It describes qualitative structural insights: APOB-100 forms an extended scaffold that wraps around the lipoprotein particle, adapts to variable lipid cargo volumes, and presents multiple interaction interfaces for the LDL receptor. These structural models reconcile prior biochemical mapping data and provide a framework for understanding familial hypercholesterolemia variants and VLDL-to-LDL remodeling, supporting the concept of APOB-100 as a dynamic structural ensemble rather than a static conformation.
Why it matters
Near-atomic visualization of APOB-100 clarifies the physical basis of LDL receptor recognition and atherogenic particle remodeling, providing structural context for genetic lipid disorders and cardiovascular risk markers.
Limits
The abstract describes a narrative review rather than primary experimental or clinical research. Fundamental limitations in structural resolution persist due to the intrinsic heterogeneity of lipoprotein particle size, lipid cargo, and protein conformational states. Details regarding cooperative receptor binding, remnant clearance, and architectures of subpopulations like lipoprotein(a) remain unmeasured and require future investigation.
Cited by
- supports There is exactly one apolipoprotein B molecule on the surface of each LDL particle.